Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3861 - Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)


10 Oct 2016


Poster display


Luis Manso Sánchez


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


L.M. Manso Sánchez1, F. Moreno Antón2, Y. Izarzugaza Perón3, J..I. Delgado Mingorance4, P. Borrega5, M.J. Echarri González6, N. Martínez7, A. López González8, C. Olier9, A. Ballesteros García10, I. Chacón11, E. Ciruelos1, J.A. García-Sáenz2, L. Paz-Ares1

Author affiliations

  • 1 Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 2 Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid/ES
  • 3 Medical Oncology, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 4 Medical Oncology, Hospital Infanta Cristina, Badajoz/ES
  • 5 Medical Oncology, Hospital San Pedro de Alcántara, Cáceres/ES
  • 6 Medical Oncology, Hospital Severo Ochoa, Leganes/ES
  • 7 Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid/ES
  • 8 Medical Oncology, University Hospital of León, Leon/ES
  • 9 Medical Oncology, HUFA Hospital Universitario Fundacion Alcorcon, Alcorcon/ES
  • 10 Medical Oncology, Hospital Universitario de La Princesa, Madrid/ES
  • 11 Medical Oncology, Hospital Virgen de la Salud, Toledo/ES


Abstract 3861


Eribulin monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapy regimen for advanced disease. In an updated analysis of the EMBRACE study, survival improved in patients with 2-3 previous regimens (13.3 months vs 10.7 months HR 0.77, P = .039).


Patients received eribulin (1.23 mg/m2 on days 1 and 8 of every 21-day cycle) as third-line therapy until progression, unacceptable toxicity or withdrawal. The primary endpoint was safety, and secondary endpoints included objective response rate, clinical benefit, 1-year overall survival and progression free survival (PFS) rates, and circulating tumour cell levels (EudraCT number 2013-001416-30).


Out of 59 eligible women (mean age 57.7), 58 (98.3%) had received previous taxanes and/or anthracyclines. Nearly all (98.3%) had HER2-negative tumors, 72% were positive for estrogens, 21% were triple negative; 64.4% had liver metastasis and 57.6% bone metastasis. Grade 3 or 4 hematologic adverse events were febrile neutropenia (N = 3; 5%) and neutropenia (n = 2; 3%). The most common non-hematologic adverse events were grade 1-2 asthenia (n = 2; 3%), grade 1-2 constipation (n = 2; 3%) and grade 1-2 skin rash (n = 1; 1%). Mean number of administered cycles was 6.9 ± 5.4. Follow-up was performed in 52 patients, with 19.2% (n = 10) partial response, 42.3% (n = 22) stable disease, and 38% (n = 20) progressive disease. Clinical benefit was achieved in 32 patients (61.5%). Median PFS was 5.13 months (95% CI 3.23, 8.90). After one year, 47 patients were still alive (81.03%).


Treatment with eribulin in third line chemotherapy for locally advanced or metastatic breast cancer is effective and minimally toxic, presenting a high clinical benefit rate.

Clinical trial identification

EudraCT number 2013-001416-30

Legal entity responsible for the study

Fundación Oncosur




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings